COVID-19 in a severely immunosuppressed patient with life-threatening eosinophilic granulomatosis with polyangiitis

Abstract: Immunosuppressive therapies increase the susceptibility of patients to infections. The current pandemic with severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 2) compels clinicians to develop recommendations for successful clinical management and surveillance of immunocompromised patients at high risk for severe disease progression. With only few case studies published on SARS-CoV-2 infection in patients with rheumatic diseases, we report a 25-year-old male who developed moderate coronavirus disease 2019 (COVID-19) with fever, mild dyspnea, and no major complications despite having received high-dose prednisolone, cyclophosphamide, and rituximab for the treatment of highly active, life-threatening eosinophilic granulomatosis with polyangiitis (EGPA)

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
Online-Ressource
Language
Englisch
Notes
Frontiers in immunology. - 11 (2020) , 2086, ISSN: 1664-3224

Keyword
COVID-19
SARS-CoV-2
Vaskulitis
EGPA
Immunsuppression
Rituximab
Cyclophosphamid

Event
Veröffentlichung
(where)
Freiburg
(who)
Universität
(when)
2020

DOI
10.3389/fimmu.2020.02086
URN
urn:nbn:de:bsz:25-freidok-1675147
Rights
Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
25.03.2025, 1:47 PM CET

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Time of origin

  • 2020

Other Objects (12)